Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

SARS-CoV-2 has caused the global COVID-19 pandemic. Although passively delivered neutralizing antibodies against SARS-CoV-2 show promise in clinical trials, their mechanism of action in vivo is incompletely understood. Here, we define correlates of protection of neutralizing human monoclonal antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Winkler, Emma S., Gilchuk, Pavlo, Yu, Jinsheng, Bailey, Adam L., Chen, Rita E., Chong, Zhenlu, Zost, Seth J., Jang, Hyesun, Huang, Ying, Allen, James D., Case, James Brett, Sutton, Rachel E., Carnahan, Robert H., Darling, Tamarand L., Boon, Adrianus C.M., Mack, Matthias, Head, Richard D., Ross, Ted M., Crowe, James E., Diamond, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879018/
https://www.ncbi.nlm.nih.gov/pubmed/33691139
http://dx.doi.org/10.1016/j.cell.2021.02.026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879018/
https://www.ncbi.nlm.nih.gov/pubmed/33691139
http://dx.doi.org/10.1016/j.cell.2021.02.026

Ejemplares similares